AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04564495 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Seated exercise
Description: Exercise will include repetitive bouts of high intensity exercises with intermittent periods of rest or active recovery. circuit of moves like 'jabs', 'hooks' etc, and a strength and endurance class that promotes postural awareness.
Study NCT05616026 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control
Description: 6 months of texts for general health promotion
Study NCT06500975 — intervention group
Intervention type: DEVICE
Intervention: Labyrinth Devices MVI™ Multichannel Vestibular Implant System
Description: Continuously motion-modulated stimulation delivered by a vestibular implant already implanted under a prior study protocol (Labyrinth Devices MVI™ Multichannel Vestibular Implant System)
Study NCT05458011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection
Study NCT05255653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg twice daily for one year
Study NCT05255653 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic external beam radiotherapy
Description: 45.0-48.6 Gy; 1.8-2.0 Gy per fraction, 5 fractions a week
Study NCT05255653 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic external beam radiotherapy
Description: 45.0-48.6 Gy; 1.8-2.0 Gy per fraction, 5 fractions a week
Study NCT05255653 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Pelvic external beam radiotherapy
Description: 45.0-48.6 Gy; 1.8-2.0 Gy per fraction, 5 fractions a week
Study NCT05255653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Preferably concurrent and adjuvant according to the PORTEC-3 schedule: two cycles of intravenous cisplatin 50mg/m² in the first and fourth week of the pelvic external beam radiotherapy followed by four cycles of intravenous carboplatin AUC 5 and paclitaxel 175 mg/m² at 21-day intervals.
Study NCT05255653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Preferably concurrent and adjuvant according to the PORTEC-3 schedule: two cycles of intravenous cisplatin 50mg/m² in the first and fourth week of the pelvic external beam radiotherapy followed by four cycles of intravenous carboplatin AUC 5 and paclitaxel 175 mg/m² at 21-day intervals.
Study NCT05255653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg intravenous once every 4 weeks for in total 1 year (13 cycles) starting within the first week of radiotherapy,
Study NCT05255653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone Acetate
Description: Oral medroxyprogesterone acetate for two years
Study NCT05255653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate
Description: Oral medroxyprogesterone acetate for two years
Study NCT05255653 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal brachytherapy
Description: Vaginal brachytherapy is to be considered in patients with documented cervical stromal involvement and/or substantial LVSI. Brachytherapy is given with a vaginal cylinder or vaginal ovoids or ring applicator, according to the center's standard technique. When using a cylinder, the active length will ideally be 2-3 cm, with the reference isodose covering the proximal 2.5-3 cm of the vagina. High-dose-rate (HDR) and pulse-dose-rate (PDR) schedules are permitted, which deliver an EQD2 equivalent dose of 10-14 Gy at 5 mm from the vaginal mucosa (to obtain a cumulative EDQ2 of 60 Gy at 5 mm).
Study NCT05255653 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Vaginal brachytherapy
Description: Vaginal brachytherapy is to be considered in patients with documented cervical stromal involvement and/or substantial LVSI. Brachytherapy is given with a vaginal cylinder or vaginal ovoids or ring applicator, according to the center's standard technique. When using a cylinder, the active length will ideally be 2-3 cm, with the reference isodose covering the proximal 2.5-3 cm of the vagina. High-dose-rate (HDR) and pulse-dose-rate (PDR) schedules are permitted, which deliver an EQD2 equivalent dose of 10-14 Gy at 5 mm from the vaginal mucosa (to obtain a cumulative EDQ2 of 60 Gy at 5 mm).
Study NCT05458011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection
Study NCT05458011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection
Study NCT06237257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: SHR-1316（Adebrelimab Injection）
Study NCT06237257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin Injection/Carboplatin Injection
Description: Cisplatin Injection/Carboplatin Injection
Study NCT06237257 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy (EBRT)/Brachytherapy
Description: External Beam Radiotherapy (EBRT)/Brachytherapy
Study NCT06237257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Injection
Description: Paclitaxel Injection.
Study NCT05869851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pavlik Harness
Description: The Pavlik harness is an abduction brace used for treatment of hip dysplasia in infants. It keeps the hips in proper alignment to allow for appropriate growth and development of the joint.
Study NCT05255653 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Vaginal brachytherapy
Description: Vaginal brachytherapy is to be considered in patients with documented cervical stromal involvement and/or substantial LVSI. Brachytherapy is given with a vaginal cylinder or vaginal ovoids or ring applicator, according to the center's standard technique. When using a cylinder, the active length will ideally be 2-3 cm, with the reference isodose covering the proximal 2.5-3 cm of the vagina. High-dose-rate (HDR) and pulse-dose-rate (PDR) schedules are permitted, which deliver an EQD2 equivalent dose of 10-14 Gy at 5 mm from the vaginal mucosa (to obtain a cumulative EDQ2 of 60 Gy at 5 mm).
Study NCT05255653 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: No adjuvant therapy
Study NCT05119985 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral vein cannulation
Description: The target vein is directly identified by ultrasound, the procedure of peripheral venous catheter insertion is performed conventionally, without ultrasound guidance
Study NCT05119985 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cannulation without ultrasound
Description: Cannulation is done the conventional way without any ultrasound use.
Study NCT06293924 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pericardiocentesis
Description: Enrolled patients will not undergo any invasive investigations outside of normal clinical practice. Patients with acute pericarditis and non-inflammatory pericardial effusion will undergo pericardiocentesis for diagnostic or therapeutic purposes.~Four ml of pericardial fluid will be collected: 2 ml for biochemical analysis in lithium heparin or serum-gel separator-associated tubes, and 2 ml for cellular analysis in K3 EDTA tubes.
Study NCT06293924 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pericardiotomy
Description: During any type of cardiac surgery involving pericardiotomy, 4 ml of pericardial fluid will be collected and analyzed upon opening the pericardial sac of enrolled patients.~Four ml of pericardial fluid will be collected: 2 ml for biochemical analysis in lithium heparin or serum-gel separator-associated tubes, and 2 ml for cellular analysis in K3 EDTA tubes.
Study NCT06293924 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cytofluorometry and Gene expression analysis
Description: A 30 ml sample of peripheral venous blood in K3 EDTA tubes will be collected by enrolled patients who participating in the translational substudy and stored with pericardial fluid samples.~Pericardial fluid cells by lineage and expression of inflammatory cytokines will be characterized through cytofluorometry and expression profile analysis of transcribed RNAs. Cytokine concentrations in peripheral blood and pericardial fluid will be analyzed by molecular assay. Peripheral blood mononucleated cells (PBMCs) and pericardial fluid cells will be cultured in vitro and exposed to the main therapies used during pericarditis, to verify the effects on gene expression and inflammatory molecules.
Study NCT06419231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Butyrate Formulation
Description: Butyrate Formulation capsule: Take daily
Study NCT06419231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Butyrate + Polyphenol Formulation
Description: Butyrate + Polyphenol Formulation capsule: Take daily
Study NCT06419231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: Take daily
Study NCT06206213 — intervention group
Intervention type: BEHAVIORAL
Intervention: Assessment of two different locomotion types.
Description: Exposure to virtual environment by the HMD in two different locomotion styles.
Study NCT06134167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transdermal Compress Device
Description: Study participants will undergo surgical implantation of the Transdermal Compress device on Study Day 1. Participants will be followed through the end of the study as they complete rehabilitation.
Study NCT05007717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Data-informed Stepped Care (DiSC)
Description: The DiSC intervention is comprised of a data-driven system to assign adolescents to care based on their health needs and the different levels of care for each assignment group.~The trajectory of services moves from a relative position of ALHIV autonomy to more intensive service provision. Intervention steps start with 1) multi-month refills or community treatment delivery (differentiated care); 2) a standard of care level for those with medical needs such as pregnancy or opportunistic infections or patient choice; 3) patient reminders/tracking and counseling and referral services for mental health needs; 4) case management of unsuppressed individuals, including enhanced counseling and case conference problem-solving
Study NCT04931212 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FETO with Smart-TO balloon
Description: Fetal endoscopic tracheal occlusion using the Smart-TO balloon Unplug procedure by peripheral course around the MR scanner
Study NCT05005442 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/vibostolimab coformuation
Description: Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.
Study NCT04953052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: An isotonic sterile solution of imatinib.
Study NCT04953052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An isotonic sterile solution
Study NCT05088863 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: flaxseed
Description: 40g of flaxseed per day
Study NCT06191978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: Given by PO
Study NCT06191978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO
Study NCT06686875 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Patients will receive a link to a web-based questionnaire on the prevalence and characteristics of pain symptoms including the PainDETECT questionnaire.
Study NCT06696430 — intervention group
Intervention type: BEHAVIORAL
Intervention: Educational Intervention on TENS Usage
Description: Educational sessions on TENS usage and support from designated superusers to increase knowledge and skills related to TENS for postoperative pain management.
Study NCT06696430 — intervention group
Intervention type: BEHAVIORAL
Intervention: Nudging Intervention to Promote TENS Usage
Description: Healthcare staff exposed to nudging strategies designed to enhance the use of TENS, which involves visual prompts, reminders, and environmental cues aimed at making TENS more salient and encouraging its use for postoperative pain management.
Study NCT06698094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sustainable lifestyle
Description: To encourage and nudge a sustainable lifestyle in an office context in order to improve public health and combat climate change.
Study NCT06698094 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy lifestyle
Description: To encourage and nudge a healthy lifestyle in an office context, the participants in this arm will function as a control group receiving general recommendations based on NNR 2014 nutritional recommendations and WHO physical activity recommendations.
Study NCT06697262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote temperature monitoring device
Description: * Use of the Tucky® remote monitoring device for continuous temperature monitoring at home,~* In combination with education sessions on temperature monitoring and the device.
Study NCT06697262 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Home temperature monitoring by a nurse
Description: * Home temperature monitoring by a nyrse, twice a day,~* In association with education sessions on temperature monitoring.
Study NCT06697366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome injection Ⅱ
Description: 56.6 mg/m2，Q3W
Study NCT06697366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg，Q3W
Study NCT05657054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention Targeting Hip Strengthening
Description: An initial 16-week exercise intervention of 45 minutes of training 3 times a week in the patient's own home or at a rehabilitation center. Patients will be instructed by a physiotherapist during the first 3 sessions, in order to be able to perform the exercises at home. Subsequently, there are physiotherapist-supervised sessions once every second week. The delivery of the supervised sessions is based on the patient's preferences, either by physical attendance or remotely in the patient's home. The intervention will consist of 4 exercises adapted from the NEMEX program targeting lower extremity muscle strength, stability, postural function, and postural orientation. Progression is made when an exercise is performed with good sensorimotor control and good performance quality and with minimal exertion and adequate movement control. Progression is primarily provided by 3 levels of difficulty and secondly by varying the number of repetitions or where possible, by increasing the weight load.
Study NCT05657054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The intervention will consist of a rehabilitation intervention corresponding to standard care in the participating municipalities (i.e. content and duration of intervention). The intervention will be delivered individually or as group training, based on a clinical assessment of the individual patients' needs. The intervention can be supported by home-based exercises following instruction from a physiotherapist, supplemented by the provision of written information or access to a virtual training program. The intervention occurs in either the rehabilitation center's gym or the patient's home. The training sessions may consist of some of the following parameters: Strength training, stretching, functional training e.g. walking and stair climbing, stability training, balance training, endurance training, and gait correction.
Study NCT05942027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo match Coenzyme Q10 capsules once per day .
Study NCT05942027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co-Enzyme Q10
Description: Patients will be treated with Coenzyme Q10 capsules (CoQ10) 200 mg/day.
Study NCT06080048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOR102
Description: SOR102 capsules
Study NCT06080048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules
Study NCT06544057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-MI
Description: CBT-MI combines elements from Cognitive Behavioural Therapy and Motivational Interviewing in treating nicotine addiction, delivered remotely via Zoom by trained 'layperson coaches'
Study NCT06245629 — intervention group
Intervention type: DRUG
Intervention: Bortezomib-bendamustine-melphalan
Description: The aim of this retrospective cohort study is to evaluate the efficacy and safety of the conditioning regimen BBM compared to HDM in the setting of relapsed multiple myeloma.
Study NCT06697522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine Sulfate
Description: low concentration atropine (0.01%)
Study NCT06697522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blank comparator
Study NCT06696651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical myostimulation
Description: Electrical myostimulation in form of suit as in fig. Blue lines demonstrate areas of electrodes inside suit. twenty females will receive EMS session per week ( 20mins / week ) and following healthy diet for 6 weeks . 20 min = 1 min warm up, 6min upper body training, 6min lower body training, 6min core training, 1 min cooling down.
Study NCT06696651 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic cupping
Description: Twenty females will undergo two weekly myofascial release sessions and a healthy diet for six weeks, using electronic cupping to ensure equal pressure on tender points.
Study NCT06696651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: healthy diet
Description: The MedDiet diet focuses on high fat intake, primarily from extra-virgin olive oil, in vegetable dishes, and a high consumption of low-glycemic index carbohydrates like wholegrain cereals, legumes, nuts, fruits, and vegetables. Moderate to high fish consumption is also encouraged, with moderate to small amounts of poultry and dairy products. Red meat and meat products are limited or avoided.
Study NCT06696651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: healthy diet
Description: The MedDiet diet focuses on high fat intake, primarily from extra-virgin olive oil, in vegetable dishes, and a high consumption of low-glycemic index carbohydrates like wholegrain cereals, legumes, nuts, fruits, and vegetables. Moderate to high fish consumption is also encouraged, with moderate to small amounts of poultry and dairy products. Red meat and meat products are limited or avoided.
Study NCT06697769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: breastfeeding simulation with virtual reality glasses
Study NCT06697860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radial Shockwave Therapy
Description: In Group A, Radial Shockwave Therapy (RST) was given to the plantar fascia for 5 minutes, with each session consisting of 5-10 shock wave pulses of varied intensity. Following that, stretching exercises for the plantar fascia and calf muscles were done for 30 minutes, with three sets of 30-second holds for each stretch. This therapy procedure was followed out in weekly sessions for 8 weeks, each lasting 40 minutes in total.
Study NCT06697860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graston Instrument
Description: Group B employed Graston Instrument-Assisted Soft Tissue Mobilization (IASTM) for 5-10 minutes to target and break down plantar fascia adhesions. The therapist used a specialized device to apply controlled, precise pressure to the fascia. Following that, stretching exercises for the plantar fascia and calf muscles were done for 30 minutes, with three sets of 30-second holds for each. The entire therapy procedure was carried out in weekly sessions for 8 weeks, each lasting 40 minutes in total..
Study NCT06696703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human urinary kininogenase(HUK)
Description: Experimental group (HUK plus routine clinical treatment): administered within 48 hours of AIS onset, 0.15PNA unit was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day.
Study NCT06696703 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group (Normal sodium chloride injection plus routine clinical treatment): Normal sodium chloride administered within 48 hours of AIS onset, by intravenous infusion for not less than 50 minutes, once a day.
Study NCT06696482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 10mg
Description: Escitalopram 10 mg, encapsulated in an opaque capsule to facilitate blinding of participant and researcher
Study NCT05343013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: GIven by PO
Study NCT06540014 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention is made, groups are formed just due to the races.